JACOBS LEVY EQUITY MANAGEMENT, INC
Position in ALLO — Allogene Therapeutics, Inc.
CIK 884414
FLORHAM PARK, NJ
Position in ALLO
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$3,026,614
-$1,886,345 QoQ
Shares Held
1,455,103
-27.7% QoQ
Ownership
0.421%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#40
of 209 holders
Holding Since
Mar 2022
6 quarters on record
Voting authority
Sole 66%
Shared 0%
None 34%
Common Shares in ALLO Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026JACOBS LEVY EQUITY MANAGEMENT, INC holds $740,535,030 across 80 Biotechnology names. ALLO ranks #35 (0.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
256,503 | $159,939,880 | |
| 2 | RARE |
Ultragenyx Pharmaceutical Inc.
|
2,939,719 | $98,157,217 | |
| 3 | INCY |
Incyte Corp
|
731,774 | $82,953,900 | |
| 4 | CORT |
Corcept Therapeutics Inc
|
695,532 | $60,476,507 | |
| 5 | HALO |
Halozyme Therapeutics, Inc.
|
322,377 | $25,232,447 | |
| 6 | EXEL |
Exelixis, Inc.
|
415,650 | $22,615,516 | |
| 7 | AUPH |
Aurinia Pharmaceuticals Inc.
|
1,231,516 | $20,898,826 | |
| 8 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
60,986 | $18,358,615 |
All Filings in ALLO
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3,026,614 | 1,455,103 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $4,912,959 | 2,013,508 | Shares | Sole | 2026-05-15 | |
| 2024-06-30 | $2,047,965 | 878,955 | Shares | Sole | 2024-08-14 | |
| 2022-12-31 | $70,554 | 11,217 | Shares | Sole | 2023-02-14 | |
| 2022-09-30 | $5,781,974 | 535,368 | Shares | Sole | 2022-11-15 | |
| 2022-03-31 | $2,466,414 | 270,737 | Shares | Sole | 2022-05-16 | |
| No filing history on record for this holder in this stock. | ||||||